HC Wainwright Reaffirms “Neutral” Rating for CytomX Therapeutics (NASDAQ:CTMX)

HC Wainwright restated their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a report released on Monday morning,Benzinga reports. HC Wainwright also issued estimates for CytomX Therapeutics’ Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at $0.14 EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.12) EPS.

CytomX Therapeutics Trading Down 1.0 %

CTMX stock opened at $1.00 on Monday. The firm’s 50-day moving average is $1.13 and its two-hundred day moving average is $1.46. The company has a market capitalization of $78.26 million, a price-to-earnings ratio of 5.94 and a beta of 1.06. CytomX Therapeutics has a 52 week low of $0.98 and a 52 week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million during the quarter, compared to the consensus estimate of $18.92 million. During the same period in the prior year, the firm posted $0.04 earnings per share. On average, equities research analysts predict that CytomX Therapeutics will post -0.13 earnings per share for the current year.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. US Bancorp DE bought a new stake in shares of CytomX Therapeutics in the 3rd quarter worth approximately $40,000. SG Americas Securities LLC acquired a new position in CytomX Therapeutics in the first quarter worth approximately $57,000. XTX Topco Ltd increased its holdings in shares of CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 48,033 shares in the last quarter. Forefront Analytics LLC lifted its position in shares of CytomX Therapeutics by 206.7% during the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 43,176 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of CytomX Therapeutics by 96.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 40,309 shares in the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.